# NanO2 for Large Vessel Occlusion Stroke

> **NCT05389748** · PHASE2,PHASE3 · UNKNOWN · sponsor: **NuvOx LLC** · enrollment: 300 (estimated)

## Conditions studied

- Ischemic Stroke

## Interventions

- **OTHER:** Placebo
- **BIOLOGICAL:** dodecafluoropentane emulsion (DDFPe)

## Key facts

- **NCT ID:** NCT05389748
- **Lead sponsor:** NuvOx LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-04-01
- **Primary completion:** 2025-04-01
- **Final completion:** 2025-09-01
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2022-05-25

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05389748

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05389748, "NanO2 for Large Vessel Occlusion Stroke". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05389748. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*